Accessibility Menu
Soleno Therapeutics logo

Soleno Therapeutics(NASDAQ) SLNO

This security has been delisted. This page is retained for historical reference.

Soleno Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 53.012026-05-15
Soleno Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.11%USD 52.952026-05-08
1 month+0.84%USD 52.572026-04-15
3 month+42.35%USD 37.242026-02-13
Year to date+14.49%USD 46.302025-12-31
1 year-29.39%USD 75.072025-05-15
3 year+1,243.73%USD 3.952023-05-16
5 year+263.92%USD 14.572021-05-14
Since inception-82.37%USD 300.752014-11-14

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

SLNO Financials

Key Financial Metrics (TTM)

Gross Margin

98.63%

Operating Margin

30.80%

Net Income Margin

33.70%

Return on Equity

22.86%

Return on Capital

3.30%

Return on Assets

15.79%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$281.11M

Operating Income

$87.77M

EBITDA

$107.01M

Operating Cash Flow

$105.71M

Capital Expenditure

-$108.00K

Free Cash Flow

$105.60M

Cash & ST Invst.

$255.60M

Total Debt

$4.41M

Soleno Therapeutics Performance Analysis

Soleno Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 190,405,000N/A
Soleno Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30102.2%
Q42025-12-3138.9%
Q12026-03-313.1%
Soleno Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.87-50.7%
20232023-12-31USD -2.36-17.5%
20242024-12-31USD -4.3885.2%
20252025-12-31USD 0.39N/A
Soleno Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3090.2%
Q32025-09-30603.8%
Q42025-12-3170.2%
Q12026-03-31-26.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$94.60M

N/A

Gross Profit

$93.41M

N/A

Gross Margin

98.73%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

115

N/A

Net Income

$31.38M

+171.7%

EBITDA

$36.72M

+187.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$255.60M

-11.8%

Total Debt

$4.41M

-91.7%

Accounts Receivable

$47.14M

N/A

Inventory

$17.31M

N/A

Long Term Debt

$3.24M

-93.8%

Short Term Debt

$1.16M

+94.8%

Return on Assets

15.79%

N/A

Return on Invested Capital

15.95%

N/A

Free Cash Flow

$25.94M

+179.2%

Operating Cash Flow

$25.98M

+179.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PRAXPraxis Precision Medicines, Inc.
$325.30+0.90%
DYNDyne Therapeutics, Inc.
$24.44+2.30%
AAPGAscentage Pharma Group International
$18.29-5.36%
APGEApogee Therapeutics, Inc.
$134.28+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.